These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 6166278)

  • 21. Toxicity studies with human leukocyte interferon in newborn rabbits.
    Pyhälä L; Rimaila-Pärnänen E; Kekomäki R; Kostiainen E; Cantell K
    Acta Pathol Microbiol Scand C; 1978 Apr; 86(2):45-51. PubMed ID: 696330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human fibroblast interferon for clinical trials: pharmacokinetics and tolerability in experimental animals and humans.
    Billiau A; De Somers P; Edy VG; De Clercq E; Heremans H
    Antimicrob Agents Chemother; 1979 Jul; 16(1):56-63. PubMed ID: 475375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Smallpox vaccination with protection by interferon and an interferon inducer].
    Bektemirov TA; Burgasova MP; Kuznetsov VP; Rozina EE; Andzhaparidze OG
    Vopr Virusol; 1980; (1):76-8. PubMed ID: 6158179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-appearance of injected fibroblast interferon in circulation.
    Edy VG; Billiau A; De Somer P
    Lancet; 1978 Feb; 1(8061):451-2. PubMed ID: 75485
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacokinetics of human leukocyte interferon.
    Cantell K; Pyhälä L
    J Infect Dis; 1976 Jun; 133 Suppl():A6-12. PubMed ID: 932506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon: pharmacokinetics and toxicity.
    Scott GM
    Philos Trans R Soc Lond B Biol Sci; 1982 Sep; 299(1094):91-107. PubMed ID: 6183699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of liver in the catabolism of human alpha- and beta-interferon.
    Bocci V; Pacini A; Bandinelli L; Pessina GP; Muscettola M; Paulesu L
    J Gen Virol; 1982 Jun; 60(Pt 2):397-400. PubMed ID: 6180128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Affinity chromatography of human leukocyte and diploid cell interferons on sepharose-bound antibodies.
    Berg K; Ogburn CA; Paucker K; Mogensen KE; Cantell K
    J Immunol; 1975 Feb; 114(2 Pt 1):640-4. PubMed ID: 1168221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Involvement of the kidney in catabolism of human leukocyte interferon.
    Bino T; Edery H; Gertler A; Rosenberg H
    J Gen Virol; 1982 Mar; 59(Pt 1):39-45. PubMed ID: 6175730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating interferon in rabbits and monkeys after administration of human gamma interferon by different routes.
    Cantell K; Hirvonen S; Pyhälä L; De Reus A; Schellekens H
    J Gen Virol; 1983 Aug; 64 (Pt 8)():1823-6. PubMed ID: 6409993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic comparison of leukocyte and Escherichia coli-derived human interferon type alpha.
    Sarkar FH
    Antiviral Res; 1982 May; 2(1-2):103-6. PubMed ID: 6179467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Binding of human interferons to immobolized Cibacron Blue F3GA: The nature of molecular interaction.
    Jankowski WJ; von Muenchhausen W; Sulkowski E; Carter WA
    Biochemistry; 1976 Nov; 15(23):5182-7. PubMed ID: 990274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of human recombinant interferon-beta in monkeys and rabbits.
    Gomi K; Morimoto M; Inoue A; Kobayashi H; Deguchi T; Hara T; Nakamizo N
    Gan; 1984 Mar; 75(3):292-300. PubMed ID: 6724230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Initial interaction of human fibroblast and leukocyte interferons with FS-4 fibroblasts.
    Gardner LJ; Vilcek J
    J Gen Virol; 1979 Jul; 44(1):161-8. PubMed ID: 227987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rabbit macrophage interferons. I. Conditions for biosynthesis by virus-infected and uninfected cells.
    Smith TJ; Wagner RR
    J Exp Med; 1967 Apr; 125(4):559-77. PubMed ID: 4163879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human leukocyte interferon administration to patients with symptomatic and suspected rabies.
    Merigan TC; Baer GM; Winkler WG; Bernard KW; Gibert CG; Chany C; Veronesi R
    Ann Neurol; 1984 Jul; 16(1):82-7. PubMed ID: 6205625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential efficacies of human type I and type II interferons as antiviral and antiproliferative agents.
    Rubin BY; Gupta SL
    Proc Natl Acad Sci U S A; 1980 Oct; 77(10):5928-32. PubMed ID: 6160587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon administered orally: protection of neonatal mice from lethal virus challenge.
    Schafer TW; Lieberman M; Cohen M; Came PE
    Science; 1972 Jun; 176(4041):1326-7. PubMed ID: 4338344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Administration of human interferon to rabies virus-infected monkeys after exposure.
    Hilfenhaus J; Weinmann E; Majer M; Barth R; Jaeger O
    J Infect Dis; 1977 May; 135(5):846-9. PubMed ID: 404370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Altered pharmacologic properties of liposome-associated human interferon-alpha. II.
    Eppstein DA
    J Interferon Res; 1982; 2(1):117-25. PubMed ID: 6180100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.